| pubmed-article:3460521 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3460521 | lifeskim:mentions | umls-concept:C1265292 | lld:lifeskim |
| pubmed-article:3460521 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:3460521 | lifeskim:mentions | umls-concept:C1318973 | lld:lifeskim |
| pubmed-article:3460521 | lifeskim:mentions | umls-concept:C0071972 | lld:lifeskim |
| pubmed-article:3460521 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:3460521 | pubmed:dateCreated | 1986-7-30 | lld:pubmed |
| pubmed-article:3460521 | pubmed:abstractText | Imipenem-cilastatin was evaluated for efficacy and toxicity as an antistaphylococcal agent in 23 patients; 11 of these patients were infected with methicillin-resistant Staphylococcus aureus (MRSA), and 12 were infected with methicillin-susceptible S. aureus (MSSA). There were 15 soft tissue, 5 endovascular, and 3 skeletal infections and a total of nine patients with bacteremia. As determined by in vitro susceptibility testing, the MICs for 90% of the MRSA and MSSA isolates tested were 6.25 and 0.39 micrograms/ml, respectively. Two MRSA isolates were resistant to a concentration of greater than 16 micrograms/ml. When 11 MRSA isolates and 7 MSSA isolates were incubated for 48 h the MICs for 90% of the isolates increased to greater than 50 micrograms/ml for the MRSA isolates and 6.25 micrograms/ml for the MSSA isolates. Three S. aureus isolates emerged resistant. Ten of 11 (91%) MRSA infections and 11 of 12 (92%) MSSA infections were clinically cured. Adverse reactions occurred in 25% of the imipenemcilastatin-treated patients. These reactions included gastrointestinal intolerance (7% of the patients), rash or pruritus (6%), eosinophilia (6%), thrombocytosis (4%), and a positive, direct Coomb test without hemolysis (3%). One of the two patients for whom therapy was discontinued because of gastrointestinal intolerance had antibiotic-associated colitis. Imipenem appears to be an effective antistaphylococcal agent against both MRSA and MSSA infections. | lld:pubmed |
| pubmed-article:3460521 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3460521 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3460521 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3460521 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3460521 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3460521 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3460521 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3460521 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3460521 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3460521 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3460521 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3460521 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3460521 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3460521 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3460521 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3460521 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3460521 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3460521 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3460521 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3460521 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3460521 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3460521 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:3460521 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3460521 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3460521 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3460521 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3460521 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3460521 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3460521 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:3460521 | pubmed:issn | 0066-4804 | lld:pubmed |
| pubmed-article:3460521 | pubmed:author | pubmed-author:LoveMM | lld:pubmed |
| pubmed-article:3460521 | pubmed:author | pubmed-author:QuinnEE | lld:pubmed |
| pubmed-article:3460521 | pubmed:author | pubmed-author:SaravolatzLL | lld:pubmed |
| pubmed-article:3460521 | pubmed:author | pubmed-author:CardenasJJ | lld:pubmed |
| pubmed-article:3460521 | pubmed:author | pubmed-author:del BustoRR | lld:pubmed |
| pubmed-article:3460521 | pubmed:author | pubmed-author:FanWW | lld:pubmed |
| pubmed-article:3460521 | pubmed:author | pubmed-author:MarkowitzNN | lld:pubmed |
| pubmed-article:3460521 | pubmed:author | pubmed-author:CendrowskiCC | lld:pubmed |
| pubmed-article:3460521 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3460521 | pubmed:volume | 29 | lld:pubmed |
| pubmed-article:3460521 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3460521 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3460521 | pubmed:pagination | 26-9 | lld:pubmed |
| pubmed-article:3460521 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:3460521 | pubmed:meshHeading | pubmed-meshheading:3460521-... | lld:pubmed |
| pubmed-article:3460521 | pubmed:meshHeading | pubmed-meshheading:3460521-... | lld:pubmed |
| pubmed-article:3460521 | pubmed:meshHeading | pubmed-meshheading:3460521-... | lld:pubmed |
| pubmed-article:3460521 | pubmed:meshHeading | pubmed-meshheading:3460521-... | lld:pubmed |
| pubmed-article:3460521 | pubmed:meshHeading | pubmed-meshheading:3460521-... | lld:pubmed |
| pubmed-article:3460521 | pubmed:meshHeading | pubmed-meshheading:3460521-... | lld:pubmed |
| pubmed-article:3460521 | pubmed:meshHeading | pubmed-meshheading:3460521-... | lld:pubmed |
| pubmed-article:3460521 | pubmed:meshHeading | pubmed-meshheading:3460521-... | lld:pubmed |
| pubmed-article:3460521 | pubmed:meshHeading | pubmed-meshheading:3460521-... | lld:pubmed |
| pubmed-article:3460521 | pubmed:meshHeading | pubmed-meshheading:3460521-... | lld:pubmed |
| pubmed-article:3460521 | pubmed:meshHeading | pubmed-meshheading:3460521-... | lld:pubmed |
| pubmed-article:3460521 | pubmed:year | 1986 | lld:pubmed |
| pubmed-article:3460521 | pubmed:articleTitle | Imipenem-cilastatin in the treatment of methicillin-sensitive and methicillin-resistant Staphylococcus aureus infections. | lld:pubmed |
| pubmed-article:3460521 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3460521 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3460521 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3460521 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3460521 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3460521 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3460521 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3460521 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3460521 | lld:pubmed |
